Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin
Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin
复制标题
DOI：
10.1016/j.canlet.2005.10.035
复制
发表时间：
2006-09-28
期刊：
影响因子：
9.7
通讯作者：
Murata, Yuji
中科院分区：
文献类型：
--
作者：
Ueno, Yuko;Enomoto, Takayuki;Murata, Yuji
评估p53突变、微卫星不稳定性和DNA错配蛋白hMLH1表达在接受紫杉醇和卡铂联合化疗的次优切除的晚期卵巢癌中的预后意义。突变型 p53 肿瘤患者的总体联合化疗有效率和完全缓解率显着高于野生型 p53 肿瘤患者（分别为 35/42（83%） vs. 32/58（55%）；P=0.003 和 18/42（43%） vs. 16/58（28%）；P=0.03）。这种趋势在非浆液性癌中明显存在，但在浆液性癌中则不存在。单变量分析显示，p53突变患者因疾病死亡的风险和疾病进展的风险显着较低（P分别为0.0357和0.0281）。然而，微卫星不稳定性的存在或 hMLH1 表达的丧失与临床反应或预后无关。确定 p53 突变状态可用于预测卵巢癌（尤其是非浆液性肿瘤）药物的治疗反应。 (c) 2005 Elsevier Ireland Ltd. 保留所有权利。
The prognostic significance of p53 mutation, microsattelite instability and DNA mismatch protein hMLH1 expression in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin was evaluated. The overall combination chemotherapy response rate and the complete remission rate were significantly higher among patients with mutant p53 tumors than those with wild-type p53 tumors (35/42 (83%) vs. 32/58 (55%); P=0.003 and 18/42 (43%) vs. 16/58 (28%); P=0.03, respectively). This tendency apparently existed in non-serous carcinoma, but not in serous carcinoma. Univariate analysis showed that the risk of death due to disease and risk of progression was significantly lower among patients with p53 mutation (P=0.0357 and 0.0281, respectively). However, the presence of microsattelite instability or loss of hMLH1 expression was not associated with either the clinical response or prognosis. Determining p53 mutational status can be useful in predicting therapeutic response to drugs in ovarian carcinoma, especially in non-serous tumors. (c) 2005 Elsevier Ireland Ltd. All rights reserved.